RT Journal Article
SR Electronic
T1 Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.02.23285205
DO 10.1101/2023.02.02.23285205
A1 Fanglei Zuo
A1 Rui Sun
A1 Hassan Abolhassani
A1 Likun Du
A1 Yating Wang
A1 Stelios Vlachiotis
A1 Federico Bertoglio
A1 Maren Schubert
A1 Nima Rezaei
A1 Zahra Chavoshzadeh
A1 Concetta Guerra
A1 Andrea Cavalli
A1 Juni Andréll
A1 Makiko Kumagai-Braesch
A1 Yintong Xue
A1 Yunlong Cao
A1 Michael Hust
A1 Davide F. Robbiani
A1 Xiaoliang Sunney Xie
A1 Lennart Hammarström
A1 Harold Marcotte
A1 Qiang Pan-Hammarström
YR 2023
UL http://medrxiv.org/content/early/2023/02/07/2023.02.02.23285205.abstract
AB The emergence of highly immune-escape Omicron variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as BQ and XBB, has led to concerns about the efficacy of vaccines. Using lentivirus-based pseudovirus neutralizing assay, we showed that heterologous vaccination involving parental mRNA vaccine as a booster or second booster in individuals that received two or three doses of inactivated vaccines strongly augments the neutralizing activity against emerging Omicron subvariants, including BF.7, BQ.1.1, and XBB.1, by 4.3-to 219-folds. Therefore, a heterologous boosting strategy with mRNA-based vaccines should be considered in populations where inactivated vaccines were primarily used.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The European Unions Horizon 2020 research and innovation program (ATAC, 101003650, D.F.R., M.H., L.H., H.M., Q.P.H), the Center for Innovative Medicine at the Karolinska Institutet (FoUI-963219, Q.P.H), the Swedish Research Council (2019-01302, 2020-06116, Q.P.H), the Knut and Alice Wallenberg Foundation (KAW2020.0102, L.H., Q.P.H), and the Magnus Bergvalls Stiftelse (2022-111, F.Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committees in institutional review board (IRB) of Stockholm, and the Tehran University of Medical Sciences.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available within the Article. All other data are available from the corresponding author upon reasonable request.